<DOC>
	<DOCNO>NCT01950481</DOCNO>
	<brief_summary>Pharmacokinetics safety 750 mg LDK378 give orally subject impair hepatic function healthy subject normal hepatic function .</brief_summary>
	<brief_title>Effect Hepatic Impairment LDK378 Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Inclusion Criteria ( group ) : Male Subjects 1870 year age Female subject 1870 year age postmenopausal sterile Body Mass Index ( BMI ) 18.0 36.0 kg/m2 , body weight â‰¥ 50 kg . Inclusion ( group mild , moderate severe hepatic impairment ) : Subjects confirm cirrhosis Exclusion Criteria ( group ) : impaired cardiac function concurrent severe and/or uncontrolled medical condition Exclusion Criteria ( moderate , mild severe group ) : Clinical evidence severe ascites Use PPIs within 10 day prior 2 day LDK378 dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>LDK378</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>